OtherEditorially reviewed · 1. Mai 2026

AOD-9604

Also known as Advanced Obesity Drug 9604, hGH Fragment 176-191, Tyr-hGH 177-191

not approvedEvidence · early clinical studies2 studies citedWADA-listed

Structure · schematic

Peptide chain of 16 amino acids · Sonstiges

Sequence

YLRIVQCRSVEGSCGF

Schematic representation of the amino acid chain — not a chemical structural formula. Each node represents one amino acid (shown truncated).

Research areas*

Metabolism

* Contexts in which the peptide has been scientifically studied — not assured or recommended effects.

§ 1

Mechanism of action

  • AOD-9604 is a synthetic peptide fragment corresponding to the C-terminal region of human growth hormone (hGH, amino acids 177–191).
  • In preclinical studies, this fragment was described as mediating lipolytic (fat-degrading) effects in adipocytes without triggering the anabolic or growth-promoting effects of the full GH molecule.
  • A postulated mechanism of action involves interactions with beta-3 adrenergic receptors on fat cells.
  • GH receptor binding and IGF-1 stimulation are absent because the GH-binding domain is missing.
§ 2

Research status

  • AOD-9604 went through a full clinical development programme run by Metabolic Pharmaceuticals (Australia).
  • Phase I studies showed favourable tolerability.
  • However, a Phase IIb study (n=536) over 24 weeks in obesity showed no significant difference from placebo in weight reduction.
  • The programme was discontinued.
  • In Australia, AOD-9604 was temporarily approved as a Novel Food ingredient (FSANZ); this status was later revoked.
  • As of February 2026, AOD-9604 was reclassified in the US by HHS/FDA into a category that again permits compounding pharmacies — which has driven increased interest on social media.

Evidence level

PreclinicalEarly clinicalEstablished
§ 3

Cited studies

  1. 2001
    Metabolic effects of growth hormone peptide analogues in obese adults
  2. 2004
    A placebo-controlled trial of the effect of hGH fragment (AOD9604) on adiposity and body composition in obese adults
§ 4

Known risks

  • 01Phase III efficacy in obesity failed — clinical benefit not established
  • 02Long-term safety data are lacking
  • 03Product quality and purity cannot be verified from unapproved sources
  • 04Possible interactions with other hormone systems not fully studied
  • 05Legal risk: WADA-listed; import may fall under the German Medicines Act (AMG)
§ 5

Frequently asked questions

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment corresponding to the C-terminal region of human growth hormone (hGH, amino acids 177–191).

What type of peptide is AOD-9604?

AOD-9604 belongs to the Other class.

Is AOD-9604 legal in Germany?

AOD-9604 is not approved as a medicine in Germany. Obtaining it outside clinical studies is legally problematic.

Where can I buy AOD-9604?

Peptica sells nothing and names no sources. AOD-9604 is "not approved" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.

Is AOD-9604 banned in sport (WADA)?

Yes. AOD-9604 is on the WADA Prohibited List and is therefore banned in competitive sport.

What are the known risks of AOD-9604?

Documented risks include: Phase III efficacy in obesity failed — clinical benefit not established; Long-term safety data are lacking. This is not a complete safety assessment and not medical advice — see the risks section for the full list.

How well researched is AOD-9604?

The evidence is classified as “early clinical studies”. 2 studies are cited on this page.

What is the molecular weight of AOD-9604?

AOD-9604 has a molar mass of about 1815.1 Da.

Which peptides are related to AOD-9604?

Closely related entries: Tesamorelin. A direct side-by-side comparison is available via the compare function.

Related entries

Legal status

Germany

not approved

Austria

not approved

Switzerland

not approved

EU

not approved

USA

not approved

Canada

not approved
WADA-listed · S2

Legal status varies by country and can change. This is not legal advice.

Sources & methodology

  • 2 peer-reviewed studies cited, linked to PubMed where available.
  • Molecular data verified against PubChem and primary literature. PubChem CID 71300630
  • Editorial standard: no dosage guidance, no sources, evidence level stated explicitly.

Last editorially reviewed: 1 May 2026

Legal assessment

As a GH fragment, AOD-9604 is on the WADA Prohibited List (S2, section on GH-releasing factors and fragments). It is not approved as a medicine in the EU or Germany. The 2026 US FDA reclassification for compounding pharmacies has no effect on the German/European legal framework. Import and possession in Germany are legally problematic and may fall under the German Medicines Act (AMG).

Important notice

This site is intended solely for factual, scientifically oriented information about peptides. It does not constitute medical advice, does not replace a consultation with a doctor and contains no recommendations for use in humans.

This site does not sell any substances and names no sources for unapproved substances. For medical questions, please consult qualified medical professionals.

Anzeige

Reserviert für sorgfältig ausgewählte Partner — Telemedizin, Diagnostik, legale topische Anwendungen.

§ 6

Community notes

Note: These posts are user opinions and not medical advice. Posts containing dosages, therapeutic claims or purchase recommendations are removed. All entries are manually reviewed before publication.